Inmune Bio establishes global commercial framework for Ebstrocel via Uniphar agreement
INmune Bio secured a Master Services Agreement with Uniphar to facilitate international access and distribution of its stem cell therapy Ebstrocel, prioritizing named-patient programs in Europe and MENA to boost commercial scalability.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed